Go Pro
NASDAQ:FTRE

Fortrea (FTRE) Stock Price, News & Analysis

Fortrea logo
$17.69 -1.36 (-7.14%)
Closing price 04:00 PM Eastern
Extended Trading
$17.95 +0.26 (+1.50%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Fortrea Stock (NASDAQ:FTRE)

Advanced

Key Stats

Today's Range
$17.65
$19.46
50-Day Range
$15.27
$20.70
52-Week Range
$6.07
$21.39
Volume
1.25 million shs
Average Volume
1.62 million shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.75
Consensus Rating
Hold

Company Overview

Fortrea, Inc. is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services. Its small-molecule capabilities include custom synthesis, active pharmaceutical ingredient (API) production, and high-potency manufacturing. On the biologics side, the company offers cell line development, microbial and mammalian cell culture, purification, viral vector production, and fill-finish operations. Complementing these laboratory and production capacities, Fortrea delivers quality assurance, regulatory support, and supply chain management to help clients navigate stringent global regulatory environments.

With its headquarters in Horsham, Pennsylvania, Fortrea operates a network of facilities across North America, Europe, and Asia, serving a diverse international client base. These strategically located sites enable the company to provide flexible manufacturing scales—from gram-scale clinical batches to multi-metric-ton commercial volumes—while ensuring continuity of supply and localized regulatory compliance. Fortrea’s global footprint supports time-sensitive project needs and offers clients access to specialized technologies and expertise in multiple regions.

Led by Chief Executive Officer James Mullen, Fortrea’s leadership team draws on decades of experience in pharmaceutical development and manufacturing. The company’s executive management combines technical know-how with a customer-focused approach, aiming to foster long-term partnerships and drive innovation. As a newly independent entity, Fortrea continues to invest in capacity expansions and technology upgrades to meet the evolving demands of the life sciences industry.

AI Generated. May Contain Errors.

Fortrea Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

FTRE MarketRank™: 

Fortrea scored higher than 75% of companies evaluated by MarketBeat, and ranked 353rd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fortrea has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside Potential

    Fortrea has a consensus price target of $20.75, representing about 17.3% upside from its current price of $17.69.

  • Amount of Analyst Coverage

    Fortrea has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Fortrea's stock forecast and price target.
  • Earnings Growth

    Earnings for Fortrea are expected to grow by 24.71% in the coming year, from $0.85 to $1.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fortrea is -19.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fortrea is -19.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Fortrea has a PEG Ratio of 0.43. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Fortrea has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.92% of the float of Fortrea has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortrea has a short interest ratio ("days to cover") of 10.18, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortrea has recently increased by 4.98%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Fortrea does not currently pay a dividend.

  • Dividend Growth

    Fortrea does not have a long track record of dividend growth.

  • News Sentiment

    Fortrea has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Fortrea this week, compared to 5 articles on an average week.
  • Search Interest

    5 people have searched for FTRE on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Fortrea to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fortrea insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,913,490.00 in company stock.

  • Percentage Held by Insiders

    0.73% of the stock of Fortrea is held by insiders.

  • Percentage Held by Institutions

    Fortrea has minimal institutional ownership at this time.

  • Read more about Fortrea's insider trading history.
Receive FTRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortrea and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FTRE Stock News Headlines

Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified a new venture quietly incubating inside Tesla. It has nothing to do with EVs, AI, or robotics, yet it generated $12 billion in 2025 alone. Blackstone calls the broader opportunity a $23 trillion investment runway. Adam believes investors who position themselves before July 22 are early. He's also giving away a free ticker pick in his latest briefing.tc pixel
See More Headlines

FTRE Stock Analysis - Frequently Asked Questions

Fortrea's stock was trading at $17.25 at the beginning of 2026. Since then, FTRE stock has increased by 2.6% and is now trading at $17.69.

Fortrea Holdings Inc. (NASDAQ:FTRE) announced its quarterly earnings data on Wednesday, July, 29th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. The firm had revenue of $678.20 million for the quarter, compared to analysts' expectations of $647.57 million. Fortrea had a negative net margin of 3.18% and a positive trailing twelve-month return on equity of 10.72%.
Read the conference call transcript
.

Fortrea's top institutional shareholders include Ausbil Investment Management Ltd (0.24%) and Assenagon Asset Management S.A. (0.18%). Insiders that own company stock include Anshul Thakral, Thomas Pike, Peter M Neupert, Jill G Mcconnell, Robert Parks, James S Hanson and Erin L Russell.
View institutional ownership trends
.

Shares of FTRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortrea investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
7/29/2026
Today
8/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:FTRE
CIK
1965040
Fax
N/A
Employees
14,300
Year Founded
2023

Price Target and Rating

High Price Target
$26.00
Low Price Target
$9.50
Potential Upside/Downside
+17.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
20.81
P/E Growth
0.46
Net Income
-$986.20 million
Net Margins
-3.18%
Pretax Margin
-2.91%
Return on Equity
10.72%
Return on Assets
2.17%

Debt

Debt-to-Equity Ratio
1.98
Current Ratio
0.96
Quick Ratio
0.96

Sales & Book Value

Annual Sales
$2.72 billion
Price / Sales
0.62
Cash Flow
$9.21 per share
Price / Cash Flow
1.92
Book Value
$5.51 per share
Price / Book
3.21

Miscellaneous

Outstanding Shares
95,100,000
Free Float
94,406,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
1.99

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:FTRE) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners